Bookmark and Share
blaNDM-1 (geneid:13906812) - Gene BioActivity Data
Also known as: D616_p76017.
BioActivity Outcomes:
Inactive(23)
 
 
Substance Types:
Chemical(23)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 1    Data Row: 23   Total Pages: 1   
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID125011827]
[CID53346529]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
2
[SID125264854]
[CID53362019]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
3
[SID125264855]
[CID53362017]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
4
[SID125264856]
[CID53362002]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
5
[SID125264857]
[CID53362007]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
6
[SID125311270]
[CID53384688]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
7
[SID125311271]
[CID53384696]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
8
[SID125311272]
[CID53384710]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
9
[SID125311273]
[CID53384681]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
10
[SID125311274]
[CID53384726]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
11
[SID125311275]
[CID53384676]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
12
[SID125311278]
[CID53384679]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
13
[SID126723253]
[CID53495082]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
14
[SID126723254]
[CID53495084]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
15
[SID126723255]
[CID53495083]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
16
[SID131269026]
[CID54579799]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
17
[SID131269027]
[CID54579797]
MIC [4 fold reduction] 50Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
18
[SID124384965]
[CID1733268]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
19
[SID124384966]
[CID1201205]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
20
[SID124398384]
[CID53257011]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
21
[SID124767346]
[CID53308605]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
22
[SID125001870]
[CID53338906]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View
23
[SID125001871]
[CID53338912]
MIC [4 fold reduction] 100Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant New Delhi metallo-beta-lactamase-1 (NDM-1)-transformed K. pneumoniae (BAA-2146) in the presence of imipenem (synergy) [AID624082, Type: other] [gi:345105285]
View